Top 5 Pharma Stocks in India
India's pharmaceutical industry is expected to cross $130 billion by 2030. Here are the top pharma stocks based on market leadership, financial strength, long-term returns, and future growth opportunities.
Quick Summary
India's pharma sector is growing rapidly, supported by rising healthcare demand and exports. This article covers the top 5 pharma stocks in India, including Sun Pharma, Divi's Labs, Cipla, Dr. Reddy's, and Mankind Pharma, along with key metrics and growth drivers.
Think about how many medicines people rely on every single day.
One can put off buying a new home or a new car, but not medicines. India is the third-largest pharmaceutical producer in the world and exports its drugs to over 191 countries.
As of Dec 2025, the domestic pharma market is currently valued at $60 billion and is expected to cross $130 billion by FY30, while pharmaceutical exports exceeded $30.5 billion in FY25, almost 16X increase from $1.9 billion in 2000 to 2001. India also exports almost 20% of the world's generic drugs, which further strengthens its reputation as the "Pharmacy of the world.
In this blog, we will explore the Top 5 Pharma Stocks in India for 2026, considering key factors such as market leadership, financial strength, 5yr CAGR return and future growth potential.
Overview of Best 5 Pharma Stocks
Here's a quick overview of the top 5 pharma stocks in India and what makes them stand out.
1. Sun Pharmaceutical Industries
If there is one company that has put India firmly on the global pharmaceutical map, it is Sun Pharma. Dilip Shanghvi started it in 1983 with a handful of psychiatric drugs, and now it is India's biggest pharmaceutical company that has operations in more than 100 countries.
Sun Pharma is moving towards specialty medicines, unlike many other pharma shares, which are taking a slow approach. Such products normally have higher margins and less competition than standard generic medication.
The transfer is likely to help Sun Pharma become more profitable and reduce its dependence on price-sensitive generic drugs. It also gained a foothold in US market through its acquisition of Taro Pharmaceuticals.
Sun Pharma's share price has been in a long-term uptrend, which can be seen in the chart below.
As of 12.47 PM, 10 June 2026
What investors should track: US business performance, specialty drug sales, regulatory approvals, and new product launches.
Here is the Full List of Best Pharma Stocks in India
The table below lists the top 5 pharmaceutical companies on Indian stock exchanges, ranked by market capitalization.
|
Company |
Market Cap (Jun 2026) Cr |
ROE |
ROCE |
5-Year Return |
Dividend Yield |
|
Sun Pharmaceutical Industries |
₹4,27,249 |
16% |
20.5% |
161% |
0.90% |
|
Divi's Laboratories |
₹1,79,532 |
16.5% |
22% |
56% |
0.44% |
|
Cipla |
₹1,11,192 |
11.6% |
15.5% |
42% |
0.94% |
|
Dr. Reddy's Laboratories |
₹1,05,886 |
11.8% |
13.6% |
16% |
0.63% |
|
Mankind Pharma |
₹98,683 |
13.1% |
13.5% |
72%* |
0.04% |
Data Source: Screener, Market capitalization as of 9 June 2026. 5-year returns calculated from 9 June 2021 to 9 June 2026. Mankind Pharma was listed in 2023; hence, five-year returns are not available.
2. Divi's Laboratories
Unlike companies that sell their drugs to consumers, Divi's Laboratories is a manufacturer of active pharmaceutical ingredients (APIs) and a custom drug manufacturer for international pharmaceutical companies.
It has a strong balance sheet, operating profit margin of 33% in march 2026, and an export business model. It has established a solid competitive position in the API business segment through its long-term partnerships with multinational pharmaceutical companies.
Divi's Lab share price has also remained in an uptrend over the long term, despite corrections.
As of 1.18 PM, 10 June 2026
What investors should track: Export demand, API pricing trends, and new contracts from global pharmaceutical companies.
3. Cipla
Established in 1935, Cipla is one of the most trusted pharmaceutical firms in India for decades. It has an established track record in respiratory, heart care and anti-infective medicines and is building its consumer medicine business.
Cipla's reputation is particularly strong in the field of respiratory medicines and its work to make HIV treatment affordable around the world. In addition to prescription drugs, the company also distributes common household medicines that are used by families all around India.
Like mentioned pharma stocks, Cipla's share price has remained in an uptrend over the last five years (June 2021 to June 2026), with some periodic corrections. As of June 2026, the stock is still trading below its lifetime high.
As of 1.18 PM, 10 June 2026
What investors should track: US market growth, respiratory product performance, and expansion in consumer healthcare.
4. Dr. Reddy's Laboratories
Established in 1984, Dr. Reddy's Laboratories has grown to become one of the premier global pharmaceutical firms in India with operations in North America, Europe, India, and other emerging markets.
The company has also established businesses in APIs, biosimilars and pharmaceutical services, providing multiple growth drivers, along with generic medicines.
Dr. Reddy's stand is unique because of its emphasis on complex and differentiated products. During FY26, the company introduced 199 products worldwide, and was the first company to get the approval of generic semaglutide injection for Type 2 diabetes in Canada.
It also introduced the generic version of semaglutide in India, called Obeda and acquired Progynova and Cyclo-Progynova brands in the women's healthcare segment.
If you look at Dr. Reddy's share price movement, the stock doubled investors' capital between April 2022 and June 2024.
As of 1.18 PM, 10 June 2026
What investors should track: US FDA approvals, research pipeline, biosimilar opportunities, and regulatory developments.
5. Mankind Pharma
Mankind Pharma has become one of the fastest-growing pharmaceutical companies in India. The company has built an impressive consumer brand profile with products such as Manforce and Prega News, in addition to its prescription drugs. It has established a large home market through its operations in smaller towns and semi-urban areas.
The company has also acquired brands like Combihale and Daffy from Dr. Reddy's Laboratories and its specialty presence in women's healthcare has been enhanced with the acquisition of Bharat Serums and Vaccines (BSV) which are high-growth specialty segments.
Mankind Pharma has not yet completed 5 years in the stock market. However, over its 3-year listed history, the stock has shown a steady upward trend and delivered strong returns to investors.
As of 1.18 PM, 10 June 2026
What investors should track: Domestic prescription growth, integration of acquisitions, and growth in chronic disease segments.
PEOPLE ALSO READING: Top 5 Defence Stocks in India
India's Pharma Industry Outlook
-
Rising healthcare expenditure, growing insurance penetration, and awareness of preventive healthcare continue to benefit India's pharmaceutical industry. With the rising prevalence of lifestyle diseases like diabetes, hypertension, and cardiovascular disease, there is a consistent demand for medicines across the country.
-
The Economic Survey 2025-26 has estimated the Indian pharmaceutical market at $60 billion and predicts it will reach $130 billion by 2030. India is also one of the largest suppliers of generic drugs, with exports accounting for about 20% of global exports.
-
Exports remain a strong growth contributor. The pharmaceutical industry exported $30.47 billion in FY25, driven by strong demand from emerging markets, Africa, Europe, and the United States. Indian firms are also venturing into complex generics, biosimilars, and specialty medicines that offer higher margins than conventional medicines.
-
The sector is also being further supported by government initiatives. The government is promoting indigenous manufacturing of high-value pharmaceutical products and critical Active Pharmaceutical Ingredients (API) through the Production-Linked Incentive (PLI) scheme. Three bulk drug parks have been sanctioned in Andhra Pradesh, Gujarat, and Himachal Pradesh in India to build infrastructure and reduce dependence on imported raw materials.
PEOPLE ALSO READING: TOP 5 DRONE STOCKS
Final Words
Although regulatory hurdles and pricing pressures may pose challenges for the pharma sector, they are an essential component of India's long-term growth story. Firms like Sun Pharma, Divi's Laboratories, Cipla, Mankind Pharma, and Dr. Reddy's Laboratories have built solid businesses with research strengths, export capabilities, and rising demand for healthcare products.
Top pharmaceutical stocks offer stability and growth, making them a good option for long-term investors. Before investing, however, thoroughly analyze the company's fundamentals, product pipeline, valuation, and regulatory risks.